Effect of an inhaled antihistamine on exercise-induced asthma

J P R HARTLEY AND S G NOGRADY

From the Asthma Research Unit, Sully Hospital, Sully, and the Department of Tuberculosis and Chest Diseases, Welsh National School of Medicine, Llandough Hospital, Nr Penarth, South Glamorgan

ABSTRACT The ability of the H₁ receptor antagonist clemastine to prevent exercise-induced asthma (EIA) has been studied in 10 adult asthmatic subjects. Exercise was performed for eight minutes on a cycle ergometer on two occasions on each of two days. The first test each day was without premedication and the second was preceded by inhalation of 0.05% clemastine or saline placebo given single blind in random order. Ventilatory function was assessed by serial measurements of peak expiratory flow rate (PEFR) and forced expiratory volume in one second (FEV₁). All four tests for each patient were closely matched in terms of oxygen uptake and total ventilation which were monitored throughout exercise. The response to exercise after clemastine or placebo has been compared both directly and in terms of the degree of protection afforded against EIA compared with the initial test on the same day. Clemastine was significantly better than placebo for both PEFR and FEV₁. All 10 subjects had less EIA after clemastine, which suggests an important role for histamine in its production. Other mechanisms may also be involved to a variable degree in different individuals.

Although much has been learned about the mechanisms of asthma little is known of the immediate cause of increased airways obstruction which occurs in many asthmatic individuals after a brief period of exertion.

Recent work has related exercise-induced asthma (EIA) to hyperventilation and subsequent airway cooling, although it is not clear whether this would act primarily on vagal irritant receptors¹ or whether it might have a direct effect on mast cells leading to the release of active mediators such as histamine.²

We have investigated the role of histamine by the use of a specific H₁ receptor blocking agent, clemastine, having previously shown that this antihistamine, given by aerosol inhalation, is a bronchodilator and can inhibit histamine-induced bronchoconstriction.³ ⁴

Methods

Fifteen patients with stable bronchial asthma gave their informed consent to the study. All had previously been shown to have exercise-induced asthma (fall in peak expiratory flow rate, PEFR, or forced expiratory volume in one second, FEV₁, of >15% after exercise).

Patients performed two exercise tests separated by two hours on each of two study days. The initial test on each day was used to confirm that a similar degree of exercise asthma was present. If the fall in PEFR or FEV₁ was <15% after the first test, the subject was asked to attend on another occasion, or was withdrawn from the study. If, in addition, at the second visit, the fall in PEFR or FEV₁ differed by more than 15% from that at the first, then that individual's response to exercise was considered too variable and he was not included in the study.

Ten patients were considered to have reproducible EIA by the criteria outlined above, and their results form the basis of this report. Their mean age was 35 years (range 24–45 yr) and six were male. Nine patients had positive skin prick tests to two or more common allergens. No drugs were permitted within 12 hours of exercise testing, with the exception of oral or inhaled corticosteroids (four patients). No patient had taken antihistamines within four weeks of the study.
Thirty minutes after the initial control exercise test, patients inhaled 1·0 ml of either 0·05% clemastine fumarate or normal saline from a disposable Hudson nebuliser. The agents were administered single blind in random sequence for the two study days. Ninety minutes later measurements of ventilatory function were made and the second exercise test performed.

Exercise tests were carried out on an electro-magnetically braked cycle ergometer (Lode) and consisted of eight minutes of steady-state submaximal exercise as previously described. The work load was sufficient to raise the heart rate during the last minute of exercise to approximately 80% of the age-predicted maximum. Oxygen uptake was calculated at half-minute intervals by entering the results of expired gas analysis and inspired ventilation volume into a programmed calculator and a graph of total oxygen uptake against time plotted. Subsequent exercise tests were standardised by matching oxygen uptake to within 5% by adjusting the ergometer setting as exercise progressed. The tests were carried out in a laboratory whose temperature ranged from 20–24°C. The humidity of the inspired air was not measured or controlled.

The response to exercise was assessed by taking the best of three readings of PEFR (Wright peak flow meter) and FEV₁ (Vitograph dry wedge spirometer). Measurements were made five minutes and immediately before exercise, and the mean of these values used as the baseline. They were repeated immediately after exercise and at five minute intervals thereafter for 30 minutes. Predicted normal values for both indices have been taken from Cotes.

Results have been analysed by comparing the maximum falls in PEFR and FEV₁ after the second exercise test at each visit. Student’s t test for paired samples has been performed on Log₁₀ a/b where a is the lowest value of PEFR or FEV₁ after exercise and b is the value before exercise.

The data have also been examined by calculating a "% protection index" for each test day. This represents the maximum % fall in PEFR or FEV₁ after the first exercise test each day, minus the maximum % fall after the second test (after placebo or clemastine), expressed as a % of the fall after the first test. The percentage protection indices for placebo and clemastine have been compared by paired t test.

Results

The degree of airway obstruction before the first exercise challenge was similar on each study day (table 1) as were the initial values for PEFR and FEV₁ before the second, post-inhalation, exercise test each time, although clemastine caused slight bronchodilatation. There was a mean rise in PEFR of 7·5% and FEV₁ of 9·5%, both of which were statistically significant, when the second baseline values were compared with the initial baseline values on the clemastine day. On the placebo day there was a small and insignificant fall in the baseline between the first and second exercise tests.

The exercise tests, four for each patient, were closely matched both in terms of total oxygen consumption and total ventilation (table 2).

There was no significant difference in the degree of EIA between the initial control exercise tests on each study day. The mean falls in PEFR after initial exercise on saline and clemastine days were 27·0% and 26·4% respectively. The mean falls in FEV₁ were 25·6% and 24·2%.

The individual responses to exercise challenge after drug inhalation are shown in table 3. Saline produced no significant effect on the % falls of either PEFR or FEV₁, but clemastine inhalation gave a highly significant degree of protection against EIA. The mean fall in PEFR was reduced from 25·4% to 12·6% (p=0·0002) and that of FEV₁ from 22·0% to 12·2% (p=0·004). All patients experienced less EIA after clemastine as measured by both indices used, with the exception

Table 1 Lung function before exercise

<table>
<thead>
<tr>
<th>PEFR (litres/min)</th>
<th>Saline</th>
<th>p</th>
<th>Clemastine</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial baseline</td>
<td>399 ± 22 (78)</td>
<td>NS</td>
<td>404 ± 22 (79)</td>
<td>0·003</td>
</tr>
<tr>
<td>p</td>
<td>NS</td>
<td>0·003</td>
<td>NS</td>
<td>0·025</td>
</tr>
<tr>
<td>Second baseline</td>
<td>394 ± 24 (77)</td>
<td>NS</td>
<td>433 ± 24 (85)</td>
<td>2·38 ± 0·17 (73)</td>
</tr>
<tr>
<td></td>
<td>2·53 ± 0·16 (77)</td>
<td>NS</td>
<td>2·47 ± 0·16 (76)</td>
<td>2·71 ± 0·21 (82)</td>
</tr>
</tbody>
</table>

Second baseline values are those immediately before the second test each day—that is, 90 minutes after inhalation of saline or clemastine. Figures are mean values ± SE (% of predicted normal values in brackets).
Effect of an inhaled antihistamine on exercise-induced asthma

Table 2  Eight-minute exercise performance

<table>
<thead>
<tr>
<th>Day</th>
<th>Test</th>
<th>Total oxygen uptake (mmol)*</th>
<th>Total ventilation (litres BTPS)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>1</td>
<td>550 ± 26</td>
<td>360 ± 14</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>551 ± 25</td>
<td>367 ± 18</td>
</tr>
<tr>
<td>Clemastine</td>
<td>1</td>
<td>556 ± 25</td>
<td>349 ± 12</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>549 ± 26</td>
<td>354 ± 14</td>
</tr>
</tbody>
</table>

Results are mean values ± SE.
*Multiply by 22.4 to convert to ml.

Table 3  Percentage falls in PEFR and FEV₁, after exercise preceded by inhalation of saline or clemastine

<table>
<thead>
<tr>
<th>Patient</th>
<th>Saline</th>
<th>Clemastine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PEFR</td>
<td>FEV₁</td>
</tr>
<tr>
<td>1</td>
<td>14-5</td>
<td>22-4</td>
</tr>
<tr>
<td>2</td>
<td>29-1</td>
<td>28-3</td>
</tr>
<tr>
<td>3</td>
<td>28-9</td>
<td>31-5</td>
</tr>
<tr>
<td>4</td>
<td>29-6</td>
<td>30-1</td>
</tr>
<tr>
<td>5</td>
<td>38-8</td>
<td>38-8</td>
</tr>
<tr>
<td>6</td>
<td>23-2</td>
<td>13-8</td>
</tr>
<tr>
<td>7</td>
<td>14-1</td>
<td>11-4</td>
</tr>
<tr>
<td>8</td>
<td>23-1</td>
<td>13-2</td>
</tr>
<tr>
<td>9</td>
<td>28-6</td>
<td>19-3</td>
</tr>
<tr>
<td>10</td>
<td>24-0</td>
<td>10-9</td>
</tr>
</tbody>
</table>

Mean 25-4 22-0 12-6 12-2
±SE 2-3 3-1 1-9 2-2

Paired t test on log₁₀a/b, p = 0.0002 (PEFR) and p = 0.004 (FEV₁).

of the FEV₁ response of patient 6, who was the only non-atopic subject.

The mean percentage protection index for saline was −3.0% for PEFR and 15.2% for FEV₁, indicating little placebo response for the group as a whole. The mean index for clemastine was 46.2% for PEFR and 47.7% for FEV₁. Both values were significant compared with placebo (p = 0.003 and 0.002 respectively).

 Bronchodilatation, measured either in terms of absolute change in lung function or expressed as percentage improvement, did not correlate significantly with the difference in EIA between tests preceded by placebo or clemastine (p > 0.05 for both PEFR and FEV₁).

Discussion

Recent studies on exercise-induced asthma have shown the importance of hyperventilation and airway cooling, but the link between heat loss from the airways and bronchospasm is not yet clear. Both neural (vagal) and chemical mechanisms have been suggested. One possibility, which has been considered for many years, is that active mediator substances released from mast cells in the bronchi may be involved. There has been no direct evidence to support this theory. The fact that EIA is reduced when exercise is repeated at short intervals, even when lung function has returned to normal, might suggest that mediator stores become depleted and need time to be replenished. Further indirect evidence is provided by the protective effect of sodium cromoglycate against EIA in many individuals, since this drug is thought to act by stabilising mast cells, and the close correlation between bronchial hyperreactivity to exogenous histamine and exercise.

More recently, attempts have been made to look for mediators directly in peripheral blood during attacks of EIA. Histamine is the first substance to be so investigated, since sensitive enzymatic or fluorimetric assays are now available, but the reported findings are conflicting. An approach which has so far received little attention is the use of specific mediator antagonists to block EIA. The study we report here has shown that clemastine significantly reduced EIA in our group of 10 patients. Some improvement in EIA was seen in all subjects, as assessed by PEFR and FEV₁, with the exception of the FEV₁ response of patient 6. Marked protection (protection index >50%) was seen in five subjects using PEFR and six using FEV₁. No subject had a protection index above 50% with saline according to PEFR measurements, while only one did so according to the FEV₁. The placebo response in our study was therefore low, and this, together with the uniform effect of clemastine, was responsible for the highly significant result. The degree of protection afforded by clemastine for the whole group is moderate, being slightly lower than that reported for methyl xanthines and sodium cromoglycate, and much lower than that reported for salbutamol, but in the latter study, the protection index for placebo was higher than our own at 25%. We consider that the design of our trial has allowed genuine responses to be more clearly distinguished from placebo effects and the natural variation of EIA itself.

We think it unlikely that clemastine affected EIA in any way other than by blocking the action of histamine released during exercise. Although significant bronchodilatation was produced, this was of a much smaller order than we have found in patients recovering from acute severe asthma, and the improvement in lung function did not correlate individually with protection against EIA. Similarly, clemastine is unlikely to have blocked vagal reflex bronchoconstriction. Although many antihistamines possess anticholinergic activity,
clemastine has been shown to be ineffective in preventing methacholine-induced bronchoconstriction in doses similar to those used in the present study, and which were able to block the effects of inhaled histamine. Moreover, such an explanation would not accord with the variable effect of large doses of atropine or ipratropium bromide on EIA. Another possible means by which clemastine might reduce EIA relates to the in vitro studies of Lichtenstein and Gillespie. These workers found that many H1 antagonists in low doses inhibit antigen-induced histamine release from human basophils. Whether this "cromoglycate-like" effect has any relevance in vivo is unknown.

There have been few other studies of conventional antihistamines in EIA. McNeill and colleagues reported no benefit in five subjects from an intramuscular injection of mepyramine maleate given 15–30 minutes before exercise, and Sly and his colleagues refer to their own unpublished observations which also showed no apparent effect, although no details were given. Zielinski and Chodosowska found significant improvement in EIA after thiazinamium, 50 mg, given intramuscularly 30 minutes before exercise, while atropine, 2 mg intravenously five minutes before exercise had no significant effect. However, thiazinamium produced a mean improvement of 35% in lung function, which was not seen after atropine at the time interval used, and this makes the results difficult to interpret. There have been no previous reports of the effect of inhaled antihistamines on EIA. Inhalation allows a greater amount of active drug to reach the airways than is possible after parenteral administration unless undesirable side effects, particularly sedation, are produced.

We believe that the effect of the H1 antagonist clemastine on EIA indicates that histamine is involved in its pathogenesis in the majority of patients. The effect of histamine could theoretically be a direct one on smooth muscle or could occur through vagal reflex mechanisms if bronchial irritant receptors were activated by local histamine release. Four of the patients in this study have been challenged after the administration of ipratropium bromide, an anticholinergic agent, and two showed a marked reduction of EIA after a relatively low dose of 0-1 mg by inhalation. The other two had significant inhibition of EIA only after a high dose, 1-0 mg. This suggests that histamine may have both direct and reflex effects, which vary in degree between patients. The alternative theory, that both drugs are merely acting as bronchodilators in preventing EIA seems unlikely for the reasons already discussed. Also clemastine caused minimal bronchodilatation in this study, and bronchodilatation is commonly seen after low doses of ipratropium bromide, without protection against EIA.

Clemastine did not inhibit EIA completely, and while this may be because of the dosage given, it is likely that other mediator substances released from mast cells may be involved in addition to histamine. When new and specific antagonists to these mediators become available, their contribution to EIA may be more readily assessed.

We would like to thank Dr IA Campbell, Dr BH Davies, Dr GS Kilpatrick, and Dr AP Smith for allowing us to study patients under their care, and Mrs PH Roberts for typing the manuscript.

References

Effect of an inhaled antihistamine on exercise-induced asthma


Effect of an inhaled antihistamine on exercise-induced asthma.
J P Hartley and S G Nogrady

Thorax 1980 35: 675-679
doi: 10.1136/thx.35.9.675

Updated information and services can be found at:
http://thorax.bmj.com/content/35/9/675

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/